Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

Bone Marrow Transplantation volume 44, pages 89–96 (2009)Cite this article

Abstract

High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). To improve safety and efficacy of this treatment, new conditioning regimens are being developed. We retrospectively reviewed clinical data of patients with relapsed NHL treated at our institution with i.v. BU and CY (BU/CY) as conditioning regimen for autologous SCT between January 2000 and April 2005. We identified 43 patients (24 men, 19 women, median age 50) with diffuse large B-cell lymphoma (n=28), follicular lymphoma (n=8), mantle cell lymphoma (n=4) and peripheral T-cell lymphoma (n=3). Following salvage chemotherapy, there were 26 complete responses, 13 partial responses and 4 stable diseases. Median time to neutrophil and platelet recovery was 11 and 13.5 days, respectively. Treatment-related toxicities included nausea/vomiting, diarrhea and mucositis. The 100-day mortality was 9%: sepsis (n=1), pneumonia (n=1) and hepatic veno-occlusive disease (n=2). Twenty-one patients were followed until death and twenty-one surviving patients were followed for a median of 29 months (range 0.4–76). Three-year estimates of event-free survival, progression-free survival and overall survival were 35, 39 and 43%, respectively. We conclude that i.v. BU/CY is a safe and effective conditioning regimen for autologous SCT in relapsed NHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  2. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  Google Scholar 

  3. Mounier N, Gisselbrecht C . Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9 (Suppl 1): S15–S21.

    Article  Google Scholar 

  4. Sheridan WP, Boyd AW, Green MD, Russell DM, Thomas RJ, McGrath KM et al. High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. Med J Aust 1989; 151: 379–386.

    CAS  PubMed  Google Scholar 

  5. de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E . Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777–781.

    Article  CAS  Google Scholar 

  6. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154.

    Article  CAS  Google Scholar 

  7. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814–821.

    Article  CAS  Google Scholar 

  8. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    Article  CAS  Google Scholar 

  9. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS . Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486–492.

    Article  CAS  Google Scholar 

  10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.

    Article  CAS  Google Scholar 

  11. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288–1294.

    Article  CAS  Google Scholar 

  12. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.

    Article  CAS  Google Scholar 

  13. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549–555.

    CAS  PubMed  Google Scholar 

  14. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215–4222.

    Article  CAS  Google Scholar 

  15. Kroger N, Hoffknecht M, Hanel M, Kruger W, Zeller W, Stockschlader M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 1998; 21: 1171–1175.

    Article  CAS  Google Scholar 

  16. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96–102.

    Article  CAS  Google Scholar 

  17. Aggarwal C, Gupta S, Vaughan WP, Saylors BG, Salzman DE, Katz RO et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770–777.

    Article  CAS  Google Scholar 

  18. Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta J, Sierra J, Marin J et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140–151.

    Article  CAS  Google Scholar 

  19. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin′s lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  Google Scholar 

  20. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784–791.

    Article  CAS  Google Scholar 

  21. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542.

    Article  CAS  Google Scholar 

  22. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell JA et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679–685.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. M P Escalón and A Stefanovic: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

    M P Escalón, A Stefanovic, D Pereira, M Goodman & J J Byrnes

  2. Division of Biostatistics, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

    A Venkatraman

  3. Division of Hematology and Medical Oncology, Tulane University Health Sciences Center, New Orleans, LA, USA

    E S Santos

  4. Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA

    H F Fernandez

Authors
  1. M P Escalón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Stefanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Venkatraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E S Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J J Byrnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H F Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M P Escalón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escalón, M., Stefanovic, A., Venkatraman, A. et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 44, 89–96 (2009). https://doi.org/10.1038/bmt.2008.429

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.429

Keywords

This article is cited by

Search

Advanced search

Quick links